Did you arrive here by via search engine?
Click here to view the original version of this article

Click to Print This Page
(This section will not print)

Occupational Airway Diseases - Part I: Overview

Course Authors

E. Neil Schachter, M.D.

Dr. Schachter reports no commercial conflict of interest.

Estimated course time: 1 hour(s).

Albert Einstein College of Medicine – Montefiore Medical Center designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and InterMDnet. Albert Einstein College of Medicine – Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 
Learning Objectives

Upon completion of this Cyberounds®, you should be able to:

  • Define four forms of occupational airway disease (OAD)

  • Recognize three categories of agents capable of causing OAD

  • Separate OAD by the mechanisms which cause it.

 

Historically, one of the most common occupational hazards has been airway injury. It is surprising, therefore, that it remains an under-recognized event. One reason may be that airway injuries vary greatly in severity--from increases in reported respiratory symptom frequency such as rhinitis in workers in industries associated with wood dust to frank pulmonary edema and even death in individual patients (e.g., silo workers exposed to high concentrations of NO2. Most commonly these injuries present as well-recognized symptom complexes such as asthma or bronchitis.

The difficulty facing the physician who suspects an occupational airway disease is to sort out whether the illness is truly related to workplace exposure. This Cyberounds® conference hopes to provide you with information helpful to making this sort of determination.

What Are Airway Diseases?

Airway diseases associated with occupational exposures result in a number of different clinical syndromes each with unique characteristics (see Table 1).

Table 1. Characteristics of Occupational Airway Diseases.

Latent Period Sensitization Airway Hyperreactivity
Industrial Bronchitis No No +/-
Reactive Airway Dysfunction Syndrome (RADS) No No +
Bronchiolitis Obliterans No No -
Occupational Asthma No No +

While each of these syndromes is clearly defined and suitable for diagnosis, a central issue in classification revolves around the question of sensitization.

Industrial Bronchitis

Similar to its non-occupational counterpart, chronic bronchitis is defined by chronic cough and expectoration resulting from exposure to irritant gases, fumes or dusts usually at relatively low concentrations for long periods of time. This is a non-immunologic illness without a latency period and not reflecting specific sensitivity to a single agent. While cigarette smoking is often a confounding variable in assessing an individual worker with chronic bronchitis(1) epidemiologic studies from a number of industries indicate the independent effect of these symptoms, particularly when contrasting smoking and non-smoking workers.(2) This issue will be covered in our next Cyberounds®.

Reactive Airway Dysfunction Syndrome (RADS)

RADS is characterized by chronic airway obstruction and irritability, frequently resulting from a single exposure to high concentrations of gases, vapors or fumes.(3) Despite the relatively short exposure involved, abnormalities, particularly airway hyperreactivity, may persist for years. No sensitization appears to be involved.

Bronchiolitis Obliterans

Bronchiolitis obliterans is a well characterized inflammatory response of the terminal airways. Such inflammation results from a usually massive exposure to irritant gases which penetrate to the lower airways (e.g., nitrogen dioxide).(4) Characteristically after initial, relatively mild symptoms of mucous membrane irritation, pulmonary edema follows in an explosive manner. If the patient survives, bronchiolitis obliterans may develop. Resolution can occur but frequently there is persistent chronic obstructive lung disease.

Occupational Asthma

Occupational asthma has generally been defined in the narrow sense(5) of airway sensitivity to a specific occupational agent; sensitization usually follows an initial exposure period. Once established, the disease is uniquely and consistently triggered by the sensitizing agent; however, as with usual asthma, the airway is generally irritable and also responds excessively to challenge with non-specific stimulants. Early removal from the offending agent may abort the disease, however, once established, hyperreactivity frequently persists even though the worker is removed from the sensitizer.

A less restrictive definition of occupational asthma(6) suggests that it represents airway obstruction, usually reversible, caused by the inhalation of substances or materials that a worker manufactures or uses directly or that are incidentally present at the work site. For example, in the textile industry byssinosis and chronic broncitis are the result of non-immunologic airway reactions. Such a definition includes processes that are both immunologic and nonimmunologic. In principle such a definition would include individuals with pre-existing asthma whose disease is exacerbated by the workplace.

Finally, as with its more general counterpart, chronic obstructive pulmonary disease (COPD), occupational airway disease does not always fit conveniently into one of the above four categories. Overlap syndromes with elements of bronchitis, reversible bronchospasm and irreversible chronic airway obstruction may combine in any single individual, and may vary with time.

Prevalence

Asthma is a very common disease of the airways affecting up to as many as 10.6% of the general population.(7) An average of 15 days per year are lost from work or school because of this disease. Since the 1980s, a gradual increase in the morbidity and mortality of this disease has been noted in the U.S. and other countries. Although generally considered reversible, growing evidence from prospective epidemiologic studies suggests that chronic asthma can be associated with progressive lung function impairment.(8) Prevalences similar to those of asthma among adults have been documented for the symptoms of chronic bronchitis in population studies.(9) Nonspecific respiratory symptoms, such as cough and wheeze, are very common in the general population(10) but have been documented to be much more frequent (two to three times more so) in selected dusty industries.(11),(12),(13),(14),(15)

The prevalence of occupational airway disease is unknown. Some general conclusions can be made. One can expect the prevalence of bronchitic symptoms found among workers to rise with the dustiness of the industry. In a recent analysis from the Harvard Six City Study the prevalence of bronchitis was stratified by the presence or absence of persistent wheeze or asthma by the annual PM 15 level (particulate matter less than 15 um in diameter). There was a significant trend of increasing bronchitis with increasing PM 15 levels.(16)

More specifically, a study by Korn looking at occupational exposures found increasing prevalences of most respiratory symptoms (e.g., chronic cough, phlegm, persistent wheeze, dyspnea and lung faction impairment) associated with increasing exposures to gases, fumes and dust in the workplace.(17) Finally, a recent survey by Schwartz et al examining 534 patients in a Primary Care Clinic over a three month period indicated that nearly 75% of those patients reported prior occupational exposure to at least one potentially toxic agent and over 30% claimed exposure to at least four such agents.

Estimates of the prevalence of occupationally-attributable asthma among new cases of diagnosed asthma have ranged from 2-15%.(19),(20),(21) These prevalence data must be viewed in the context of individual agents where cases may vary from idiosyncratic to very frequent. For example, it has been estimated that some 5% of workers exposed to western red cedar dust develop occupational asthma,(22) whereas up to 45% of workers exposed to proteolytic enzymes may develop occupationally related asthma.(23)

Etiology and Mechanisms

Agents causing (or associated with) occupational airway diseases have been divided into three categories (see Table 2).

Table 2. Physical and Chemical Characteristics of Agents Inducing Airway Disease.

  1. Gases and Fumes (e.g., SO2, NO2, NH3).
  2. Large Molecular Weight Substances (e.g., glycoproteins, vegetable gums, animal products, plant constituents, insect constituents).
  3. Low Molecular Weight Substances (e.g., acid anhydrides, precious metals, antibiotics, isocyanates).

The clinical syndromes associated with exposure to gases and fumes tend to involve exacerbation of pre-existing asthma or RADS. Gases and fumes have well characterized irritant effects which are usually dose related, non-sensitizing and more irritating to susceptible individuals (e.g., asthmatics).(24)

Not all gases which irritate mucous membranes are equally dangerous to the airways. For example, formaldehyde is potentially far more irritating to the mucous membranes of the eyes and nose than SO2 or NO2, yet it has little or no airway effect at usual occupational levels,(25) although sensitization may occur.(26) Gases such as formaldehyde which are highly soluble and are maximally absorbed in the upper airways may not reach the lower airways in concentrations great enough to cause damage or irritation. The solubility of the gas and its ability to reach the lower airway is felt to be an important factor in promoting airway effects.

Low molecular weight compounds known to induce occupational asthma have been arbitrarily defined as having a molecular weight of less than 1000 daltons. These agents are in general simple organic molecules (e.g., isocyanates), drugs (e.g., antibiotics) or metals (e.g., platinum) used in a wide variety of industries (see Table 3a).

Table 3a. Characteristics of Low Molecular Weight Substances Associated with Occupational Airway Disease.

Substance/
Examples
Industry Etiology Tests
Specific Skin Test Specific IgE Bronchial Provocation
Isocyanates
Toluene diiso-Cyanate plastic polyurethane ? +/- +/- +
Anhydrides
Phthalic anhydride

Trimellitic anhy-Dride
plastic, rubber and resin Allergic + + +
Wood Dust
Western red cedar
California redwood
saw mills, carpentry construction ? +/- +/- +
Metals
Platinum platinum refineries Allergic +
Fluxes
Colophony electronic industries ? +
Drugs
Antibiotics pharmaceuticals Allergic +/- +
Textile Dust

Cotton

textile mills Non-immunologic - - +
Hemp release of mediators

Table 3b. Characteristics of Large Molecular Weight Substances Associated with Occupational Airway Dsease.

Substance/
Examples
Industry Etiology Tests
Specific Skin Test Specific IgE Bronchial Provocation
Animal Proteins
Lab animals laboratories, veterinary offices Allergic + + +
Fish/Shellfish fisheries, crab processing plants
Birds pigeon breeding, poultries
Insects laboratories, entomologist laboratories
Vegetable Dusts
Grain dust granaries Allergic + + +
Flour bakeries
Tea/Coffee food processing
Castor Bean oil inudstries
Enzymes
Bromelin pharmaceutical Allergic + + +
Papain laboratory
Pepsin pharmaceutical
Trypsin pharmaceutical

Examples which have been extensively studied include platinum salts,(27) acid anhydrides,(28),(29) such as trimellitic anhydride and tetrachlorophthalic anhydride, isocyanates,(30),(31) plicatic acid(32) and antibiotics.(33),(34)

In many instances it is known that these agents act by causing a classic immunologic sensitization by acting as haptens (e.g., acid anhydridres and platinum salts). For others, however, the immunologic mechanism, although suspected, has not been fully characterized (e.g., isocyanates and western red cedar). Pre-existing atopy does not appear to be a risk factor for development of disease with these agents.

Large molecular weight agents are in general proteins, peptides or polysaccharides of plant or animal origin (see Table 3b) which elicit classic humoral sensitivity via IgE or occasionally IgG antibodies. The affected individuals frequently exhibit general signs of atopy such as pre-existing allergic rhinitis or eczema. When exposed to these agents either in the natural setting or in a challenge situation the sensitized individual experiences immediate or biphasic (dual) reactions, the latter characterized by the onset of delayed airway obstruction a number of hours following challenge.

The mechanism of disease involved in asthma due to high molecu lar weight compounds is felt to be identical with asthma due to common allergens such as house dust or pollens. In such patients specific IgE antibodies develop following repeated exposure and lead to an interaction with antigen on the surface of immunoactive cells (e.g., mast cells). This in turn leads to the release of both preformed mediators (e.g., histamine, eosinophil chemotactic factor) as well as de-novo synthesized mediators (e.g., prostaglandins, leukotrienes).(35) By contrast the mechanism involved in airway disease attributable to low molecular weight agents involves inflammation(36),(37) and the role of classic IgE mediated disease is uncertain since these antibodies are not invariably associated with disease.(38),(39)

In addition to the above agents and mechanisms certain host characteristics are felt to be important in the development of occupational lung disease. The major host factors involved in pathogenesis and exacerbation are listed in Table 4.

Table 4. Host Factors Possibly Involved in the Development of Severity of Occupational Airway Disease.

  1. Atopy
  2. Cigarette smoking
  3. Airway hyperreactivity
  4. Pre-existing lung disease
  5. Genetic factors

The way in which these factors may interact with a disease mechanism are listed in Table 5.

Table 5. Possible Interaction Between Host and Risk Factors.

  1. Exacerbation of pre-existing airway disease by factor(s) in the occupational setting.
  2. Development of new airway disease as a result of factor(s) in the occupational setting.
  3. Interaction of pre-existing susceptibility, non-occupational environmental factor(s) (e.g. air-pollution, cigarette smoking) and the occupational environmental trigger to disease.

In our next Cyberounds® we will discuss a general approach to diagnosing occupational airway diseases and will examine in detail the problems faced worldwide by textile workers.


Footnotes

1Bouhuys A, Beck GJ, Schoenberg JB: Epidemiology of environmental lung disease. Yale J Biol Med 1979; 52:191-210.
2Beck GJ, Maunder LR, Schachter EN: Cotton dust and smoking effects on lung function in cotton textile workers. Amer J Epidemiol 1984; 119:33-43.
3Brooks SM, Weiss MA, Bernstein IL: Reactive airways dysfunction syndrome (RADS) Chest 1985; 88:376-383.
4Jones GR, Proudfoot AT, Hall JI: Pulmonary effects of acute exposure to nitrous fumes. Thorax 1973; 28:61-65.
5Brooks SM, Kalica AR: NHLBI Workshop Summary: Strategies for elucidating the relationship between occupational exposures and chronic air-flow obstruction. Amer Rev Respir Dis 1987; 135:268-273.
6Fish JE: Occupational Asthma: A spectrum of Acute Respiratory Disorders. JOM 1982; 24:379-386.
7Weiss KB, Wagner DK: Asthma surveillance in the United States: A review of current trends and knowledge gaps. Chest (Suppl.) 1990; 98: 179s-184s.
8Weiss ST: A framework for assessing impairment from asthma. Chest (Suppl) 1990; 98:225s-231s.
9Schachter EN, Doyle CA, Beck GJ: A prospective study of asthma in a rural community. Chest 1984; 85: 623-630.
10Beck GJ, Doyle CA, Schachter EN: A longitudinal study of respiratory health in a rural community. Amer Rev Resp Dis 1982; 125:375-381.
11Zuskin E, Skuric Z, Kanceljak B, Prokrajac D, Schachter EN, Witek TJ: Respiratory symptoms and ventilatory capacity in soy work ers. Amer J Indust Med 1988; 14:157-165.
12Zuskin E, Skuric Z, Kanceljak B, Prokrajac D, Schachter EN, Witek TJ: Respiratory findings in spice factory workers. Arch Env Health 1988; 43:335-339.
13Zuskin E, Skuric Z, Kanceljak B, Prokrajac D, Schachter EN, Witek TJ: Respiratory symptoms and lung function in furriers. Amer J Indust Med 1988; 14:189-196.
14Zuskin E, Mataija M, Prokrajac D, Schachter EN, Witek TJ: Respiratory function in animal food processing workers. Amer J Indust Med. 1989; 16:179-187.
15Zuskin E, Kanceljak B, Porkrajac D, Schachter EN, Witek TJ Jr: Respiratory symptoms and lung function in hemp workers. Br J Indust Med 1990; 47:627-632.
16Speizer FE: Asthma and persistant wheeze in the Harvard six cities study. Chest 98 (suppl): 1990; 191s-195s.
17Korn RJ, Dockery DW, Speizer FE, Ware JH, Ferris BG Jr.,: Occupational exposures and chronic respiratory symptoms. Amer Rev Respir Dis 1987; 136:298-304.
19Brooks SM: Occupational asthma. Chest 87 (suppl) 1985; 218s-225s.
20Blanc P. Occupational asthma in a national disability survey. Chest 1987; 92:613-617.
21Evan R, Mullaly DI, Wilson RW, Gergen PJ, Rosenberg HM, Grausman JS, Chevarley FM, Feinleib M: National trends in morbidity and mortality of asthma in the U.S. Chest 1987; 91 (suppl): 65s-73s.
22Chan-Yeung M, Ashley MJ, Corey P, Willson G, Dorken E, Grzybowski S: A respiratory survey of cedar mill workers. I prevalence of symptoms and lung function abnormalities. J Occup Med 1978; 20:328-332.
23Mitchell ML, Gandevia B: Respiratory symptoms and skin sensitivity in workers exposed to proteolytic enzyme in detergent industry. Amer Rev Respir Dis 1971; 104:1-12.
24Schachter EN, Witek TJ, Beck GJ, Colice G, Hosein HR, Leaderer BP, Cain W: Dose response effect of low concentrations of sulfur dioxide on airway function. Arch Envir. Health 1984; 39:34-42.
25Schachter EN, Witek TJ. Brady DJ, Tosun T, Beck GJ, Leaderer BP: A study of respiratory effects from exposure to 2.0 ppm formaldehyde in occupationally exposed workers. Env Res 1987; 44:188-205.
26Hendrick DJ, Love DJ: Formalin asthma in hospital staff. Br M J 1975; 1:607-608.
27Pepys J, Pickering CAC, Hughes EC: Asthma due to inhaled chemical agents: complex salts of platinum. Clin Allergy 1972; 2:391-396.
28Fawcett IW, Newman-Taylor AJ, Pepys J: Asthma due to inhaled chemical agents: epoxy resin systems containing phthalic acid anhydride, trimellitic acid anhydride and triethylene tetramine. Clin Allergy 1977; 7:1-14.
29Zeiss CR, Patterson R, Pruzansky JJ, Miller M, Rosenberg M, Levitz D: Trimellitic anhydride-induced airways syndromes: clinical and immunologic studies. J Allergy Clin Immunol 1977; 60:96-103.
30Pepys J, Pickering CAC, Breslin ABX, Terry DJ: Asthma due to inhaled chemical agents: toluene diisocyanate. Clin Allergy 1972; 2:225-236.
31Butcher BT, Salvaggio JE, Weill H, Ziskind MM: Toluene diisocyanate (TDI) pulmonary disease: immunologic and inhalation challenge studies. J Allergy Clin Immunol 1970; 58:89-100.
32Chan-Yeung M: Immunologic and nonimmunologic mechanisms in asthma due to western red cedar (Thuja plicata). J Allerg Clin Immunol 1982; 70:32-37.
33Davies RJ, Hendrick DJ, Pepys J: Asthma due to inhaled chemical agents: ampicillin, benzylpenicillin, 60 aminopenicillanic acid and related substances. Clin Allergy 1974; 4:227-247.
34Coutts II, Dally MB, Newman-Taylor AJ, Pickering CAC, Horsfield N: Asthma in workers manufacturing cephalosporins. Br Med J 1981; 283:950.
35Diaz P, Gonzalez MC, Gelleguillos FR, Ancic P, Cromwell O, Shepherd D, Durham SR, Gleich GJ, Kay AB: Leukocytes and mediators in bronchoalveolar lavage during allergen-induced late phase asthmatic reactions. Am Rev Respir Dis 1989; 139:1383-1389.
36Lam S, Le Riche J, Phillips D, Chan Yeung M: Cellular and protein changes in bronchial lavage fluid after late asthmatic reaction in patients with red cedar asthma. J Allergy Clin Immunol. 1987; 80:44-50.
37Fabbri LM, Boschetto P, Zocca E, Milani G, Pivirotto F, Plebanim Burlina A, Licata B, Mapp CE: Bronchoalveolar neutrophilia during late asthmatic reactions induced by toluene diisocyanate. Am Rev Resp Dis 1987; 136:36-42.
38Butcher BT, Salvaggio JE, Weill H, Zuskind MM: Toluene diisocyanate (TDI) pulmonary disease: immunologic and inhalation challenge studies. J Allerg Clin Immunol 1970; 58:89-100.
39Gallagher JS, Tse CST, Brooks SM, Bernstein IL: Diverse profiles of immunoreactivity in toluene diisocyanates (TDI) asthma. JOM 1981; 23:610-616.